Yubin Kang

Dr. Yubin Kang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
BTBalamayoora Theivanthiran
Balamayoora Theivanthiran
KEKathy S. Evans
Kathy S. Evans
NDNicholas C. DeVito
Nicholas C. DeVito
MPMichael Plebanek
Michael Plebanek
MSMichael Sturdivant
Michael Sturdivant
BHBrent A. Hanks
Brent A. Hanks
An in-depth understanding of immune escape mechanisms in cancer is likely to lead to innovative advances in immunotherapeutic strategies. However, much remains unknown regarding these mechanisms and how they impact immunotherapy resistance. Using several preclinical tumor models as well as clinical specimens, we identified a mechanism whereby CD8+ T cell activation in response to programmed cell death 1 (PD-1) blockade induced a programmed death ligand 1/NOD-, LRR-, and pyrin domain–containing protein 3 (PD-L1/NLRP3) inflammasome signaling cascade that ultimately led to the recruitment of granulocytic myeloid-derived suppressor cells (PMN-MDSCs) into tumor tissues, thereby dampening the resulting antitumor immune response. The genetic and pharmacologic inhibition of NLRP3 suppressed PMN-MDSC tumor infiltration and significantly augmented the efficacy of anti–PD-1 antibody immunotherapy. This pathway therefore represents a tumor-intrinsic mechanism of adaptive resistance to anti–PD-1 checkpoint inhibitor immunotherapy and is a promising target for future translational research.

10 April 2020 in Science
Verified
Journal Article
Closed access
PDF file
QHQiang Huang
Qiang Huang
MCMalkiel A. Cohen
Malkiel A. Cohen
FAFernando C. Alsina
Fernando C. Alsina
GDGarth Devlin
Garth Devlin
AGAliesha Garrett
Aliesha Garrett
XSXiling Shen
Xiling Shen
A window to the embryo: Mammalian embryonic development is a complex process, continuously changing in space and time. Q. Huang et al. designed an abdominal window to image mouse embryos in utero from embryonic day 9.5 to birth. Using this technique, they visualized dynamic activities during embryonic organ formation, including neurotransmission and cell division in the brain, autophagy in the retina, viral gene delivery, and placental drug transfer. They also tracked diverging fates of human and mouse neural crest cells in interspecies chimeras. Science , this issue p. 181

22 March 2024 in Science Advances
Verified
Journal Article
Open access
XZXiaoyi Zhu
Xiaoyi Zhu
QHQiang Huang
Qiang Huang
LJLaiming Jiang
Laiming Jiang
VNVan-Tu Nguyen
Van-Tu Nguyen
TVTri Vu
Tri Vu
JYJunjie Yao
Junjie Yao
Studying placental functions is crucial for understanding pregnancy complications. However, imaging placenta is challenging due to its depth, volume, and motion distortions. In this study, we have developed an implantable placenta window in mice that enables high-resolution photoacoustic and fluorescence imaging of placental development throughout the pregnancy. The placenta window exhibits excellent transparency for light and sound. By combining the placenta window with ultrafast functional photoacoustic microscopy, we were able to investigate the placental development during the entire mouse pregnancy, providing unprecedented spatiotemporal details. Consequently, we examined the acute responses of the placenta to alcohol consumption and cardiac arrest, as well as chronic abnormalities in an inflammation model. We have also observed viral gene delivery at the single-cell level and chemical diffusion through the placenta by using fluorescence imaging. Our results demonstrate that intravital imaging through the placenta window can be a powerful tool for studying placenta functions and understanding the placental origins of adverse pregnancy outcomes.

27 February 2018 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
ZZZhihong Zheng
Zhihong Zheng
SFShengjun Fan
Shengjun Fan
JZJing Zheng
Jing Zheng
WHWei Huang
Wei Huang
CGCristina Gasparetto
Cristina Gasparetto
YKYubin Kang
Yubin Kang
Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib. Increased thioredoxin level has been reported to be associated with carcinogenesis; however, the role of thioredoxin in bortezomib drug resistance of myeloma remains unclear. We generated several bortezomib-resistant myeloma cell lines by serially passaging with increased concentrations of bortezomib over a period of 1.5 years. Thioredoxin expression was measured by real-time PCR and western blot. The role of thioredoxin in the survival of bortezomib-resistant myeloma cells was determined by specific shRNA knockdown in vitro and in vivo. Thioredoxin inhibitor (PX12) was used to determine the effectiveness of thioredoxin inhibition in the treatment of bortezomib-resistant myeloma cells. The effect of thioredoxin inhibition on mitophagy induction was examined. The correlation of thioredoxin expression with patient overall survival was interrogated. Thioredoxin expression was significantly upregulated in bortezomib-resistant myeloma cells and the change correlated with the increase of bortezomib concentration. Thioredoxin gene knockdown using specific shRNA sensitized bortezomib-resistant myeloma cells to bortezomib efficiency in vitro and in vivo. Similarly, pharmacological inhibition with PX12 inhibited the growth of bortezomib-resistant myeloma cells and overcame bortezomib resistance in vitro and in vivo. Furthermore, inhibition of thioredoxin resulted in the activation of mitophagy and blockage of mitophagy prevented the effects of PX12 on bortezomib-resistant myeloma cells, indicating that mitophagy is the important molecular mechanism for the induction of cell death in bortezomib-resistant myeloma cells by PX12. Moreover, inhibition of thioredoxin resulted in downregulation of phosphorylated mTOR and ERK1/2. Finally, thioredoxin was overexpressed in primary myeloma cells isolated from bortezomib-resistant myeloma patients and overexpression of thioredoxin correlated with poor overall survival in patients with multiple myeloma. Our findings demonstrated that increased thioredoxin plays a critical role in bortezomib resistance in multiple myeloma through mitophagy inactivation and increased mTOR and ERK1/2 phosphorylation. Thioredoxin provides a potential target for clinical therapeutics against multiple myeloma, particularly for bortezomib-resistant/refractory myeloma patients.

3 April 2019 in Journal of Cancer Metastasis and Treatment
Verified
Journal Article
Open access
DRDustin Rizzieri
Dustin Rizzieri
BPBarry Paul
Barry Paul
YKYubin Kang
Yubin Kang
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.

1 May 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
LCLuciano J. Costa
Luciano J. Costa
LYLi Yin
Li Yin
RCR. Frank Cornell
R. Frank Cornell
TMThomas Martin
Thomas Martin
SCSaurabh Chhabra
Saurabh Chhabra
PHParameswaran Hari
Parameswaran Hari